상세 보기
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
- Ku, Bo Mi;
- Choi, Moon Ki;
- Sun, Jong-Mu;
- Lee, Se-Hoon;
- Ahn, Jin Seok;
- 외 2명
WEB OF SCIENCE
19SCOPUS
19초록
AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. Furthermore, AZD9291 is now being evaluated as a first-line treatment for NSCLC patients with activation EGFR mutations. Based on previous experiments, resistance to AZD9291 as a first-line treatment may also emerge. Thus, identification and understanding of resistance mechanisms to AZD9291 as a first-line treatment can help direct development of future therapies. AZD9291-resistant cells (PC9/AZDR) were established using EGFR inhibitor-naive PC9 cells. Resistance mechanisms were analyzed using next-generation sequencing (NGS) and a proteome profiler array. Resistance to AZD9291 developed through aberrant activation of ERK signaling by an EGFR-independent mechanism. The combination of a MEK inhibitor with AZD9291 restored the sensitivity of PC9/AZDR cells in vitro and in vivo. PC9/AZDR cells also showed increased MET expression and an HRAS G13R mutation. In addition, maspin expression was higher after AZD9291 treatment in PC9/AZDR cells. Sustained ERK activation confers resistance to AZD9291 as a first-line therapy. Thus, co-targeting EGFR and MEK may be an effective strategy to overcome resistance to AZD9291.
키워드
- 제목
- Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
- 저자
- Ku, Bo Mi; Choi, Moon Ki; Sun, Jong-Mu; Lee, Se-Hoon; Ahn, Jin Seok; Park, Keunchil; Ahn, Myung-Ju
- 발행일
- 2018-04-11
- 유형
- Article
- 저널명
- PLoS One
- 권
- 13
- 호
- 4
- 언어
- ENG
- 출판사
- Public Library of Science
- 발행국가
- 미국
- ISSN
- E 1932-6203